Congenital Heart Disease Clinical Trial
— SwissORCHIDOfficial title:
The Swiss Neurodevelopmental Outcome Registry for Children With CHD
Introduction: Congenital heart disease (CHD) is the most frequent birth defect. As survival has significantly improved, attention has turned to neurodevelopmental outcomes of children undergoing heart surgery in early infancy. Since multiple risk factors contribute to neurodevelopmental alterations, a nationwide registry collecting data on medical characteristics, interventions, clinical course and neurodevelopment until school-age is needed to improve the quality of management, identify risk- and protective factors affecting neurodevelopment, and facilitate multicenter trials. Methods and analysis: The Swiss Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is a nationwide, prospective, population-based patient registry developed (1) to collect baseline characteristics and clinical data of CHD patients operated with bypass-surgery or hybrid procedures in the first 6 weeks of life in Switzerland, (2) to monitor long-term neurodevelopment, and (3) to relate clinical characteristics and neurodevelopment to identify risk and protective factors in these children. This registry started data collection relating to pregnancy, birth, preoperative course, catheter-based and surgical treatment, postoperative course and reinterventions in 2019. The primary outcome includes standardised neurodevelopmental assessments at 9 to 12 months, 18 to 24 months and 5.5 to 6 years. Investigators expect to include 80 to 100 children per year. Correlation and regression analyses will be used to investigate risk- and protective factors influencing neurodevelopment. Ethics and dissemination of results: Swiss ORCHID received support by the Accentus Charitable Foundation, the Anna Mueller Grocholoski Foundation, the Swiss Society of Pediatric Cardiology, and the Corelina - Foundation and was approved by the cantonal ethics committees. Findings will be presented at national and international scientific meetings, and published in peer-reviewed journals. Results will also be shared with patient organizations, primary health care providers, and public health stakeholders to ensure a widespread dissemination of the results.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 31, 2032 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Week to 6 Weeks |
Eligibility | Inclusion Criteria: - Neonates (including preterm born children) with severe CHD - Requiring an invasive cardiac intervention (including heart-lung-machine) within the first 6 weeks of life. Exclusion Criteria: - Neonates (including preterm born children) with simple CHD - Requiring simple cardiac surgery or catheter intervention such as closure of patent arterial duct or simple repair of aortic coarctation without heart-lung-machine and low impact on neurodevelopmental outcome. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University of Bern | Bern | |
Switzerland | University of Lausanne | Lausanne | |
Switzerland | University Children's Hospital | Zurich |
Lead Sponsor | Collaborator |
---|---|
University Children's Hospital, Zurich | University of Bern, University of Geneva, Switzerland, University of Lausanne Hospitals |
Switzerland,
Natterer J, Schneider J, Sekarski N, Rathke V, Adams M, Latal B, Borradori-Tolsa BT, Bouhabib M, Fuhrer Kradolfer K, Glockler M, Hutter D, Kelly J, L'Ebraly C, Pfluger MR, Polito A, von Rhein M, Knirsch W. ORCHID (Outcome Registry for CHIldren with severe — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bayley scales of infant and toddler development III at one year of age | Neurodevelopmental outcome measurement at one year of age (normal value 100, higher values mean better outcome) | One year of age | |
Primary | Bayley scales of infant and toddler development III at two years of age | Neurodevelopmental outcome measurement at two years of age (normal value 100, higher values mean better outcome) | Two years of age | |
Primary | Bayley scales of infant and toddler development III at five years of age | Neurodevelopmental outcome measurement at five years of age (normal value 100, higher values mean better outcome) | Five years of age |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04992793 -
Paediatric Brain Injury Following Cardiac Interventions
|
||
Recruiting |
NCT05213598 -
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
|
||
Completed |
NCT04136379 -
Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
|
||
Completed |
NCT04814888 -
3D Airway Model for Pediatric Patients
|
||
Recruiting |
NCT04920643 -
High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery
|
N/A | |
Completed |
NCT05934578 -
Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training
|
N/A | |
Recruiting |
NCT06041685 -
Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia
|
N/A | |
Recruiting |
NCT05902013 -
Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation
|
N/A | |
Not yet recruiting |
NCT05687292 -
Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
|
||
Not yet recruiting |
NCT05524324 -
Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT
|
N/A | |
Completed |
NCT02746029 -
Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
|
||
Completed |
NCT02537392 -
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
|
N/A | |
Completed |
NCT03119090 -
Fontan Imaging Biomarkers (FIB) Study
|
||
Recruiting |
NCT02258724 -
Swiss National Registry of Grown up Congenital Heart Disease Patients
|
||
Terminated |
NCT02046135 -
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery
|
Phase 2 | |
Completed |
NCT01966237 -
Milrinone Pharmacokinetics and Acute Kidney Injury
|
||
Recruiting |
NCT01184404 -
Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery
|
N/A | |
Completed |
NCT01548950 -
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
|
N/A | |
Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A |